<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055921</url>
  </required_header>
  <id_info>
    <org_study_id>CL007 (US)</org_study_id>
    <nct_id>NCT05055921</nct_id>
  </id_info>
  <brief_title>MultiPulse Therapy (MPT) for AF (US)</brief_title>
  <official_title>A Clinical Feasibility Study to Evaluate the Safety and Performance of Low-Energy Therapy in Patients With Atrial Fibrillation (US)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardialen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardialen, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the clinical safety and feasibility of MultiPulse Therapy (MPT) electrical stimulation&#xD;
      waveform sequence in terminating paroxysmal and persistent atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective non-randomized feasibility study involving acute testing of MPT in subjects&#xD;
      with paroxysmal and persistent AF during clinically indicated atrial fibrillation catheter&#xD;
      ablation procedure.&#xD;
&#xD;
      Subjects will be split into 2 cohorts depending on status at time of procedure.&#xD;
&#xD;
        1. In Atrial Fibrillation at time of procedure (Clinical AF)&#xD;
&#xD;
        2. In Normal Sinus Rhythm at time of procedure&#xD;
&#xD;
      Subjects will be evaluated at the visits for the Clinically-Indicated Procedure per standard&#xD;
      of care. A single follow-up at up to 30 days post-procedure is required to assess subjects&#xD;
      for adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multi-Pulse Therapy as delivered from the Cardialen External Stimulation System (CESS)</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of MPT for the treatment of atrial fibrillation in subjects</measure>
    <time_frame>Acutely at the time of the study procedure</time_frame>
    <description>Reported Adverse Events following MPT delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety of MPT for the treatment of atrial fibrillation in subjects</measure>
    <time_frame>At 30 day post procedure</time_frame>
    <description>Reported Adverse Events following MPT delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Enhanced ability of MPT to stop atrial fibrillation</measure>
    <time_frame>Acutely following MPT delivery</time_frame>
    <description>Compare voltages at which MPT successfully terminated AF against a previous Cardialen AF study (CL001 / NCT02257112)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ability of MPT to stop atrial fibrillation</measure>
    <time_frame>Acutely following MPT delivery</time_frame>
    <description>Determine rate of conversion from AF to NSR</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Multi Pulse Therapy as delivered from the Cardialen External Stimulation System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will have AF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multi Pulse Therapy as delivered from the Cardialen External Stimulation System</intervention_name>
    <description>The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen MultiPulse Therapy (MPT). The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.&#xD;
Other Names:&#xD;
Unpinning Termination Therapy&#xD;
Multi-stage therapy&#xD;
Multi-stage electrotherapy&#xD;
MultiPulse Therapy</description>
    <arm_group_label>Multi Pulse Therapy as delivered from the Cardialen External Stimulation System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female between 18 and 80 years of age&#xD;
&#xD;
          2. Willing and able to comply with the study protocol, provide a written informed consent&#xD;
&#xD;
          3. Currently indicated for atrial catheter ablation due to paroxysmal or early persistent&#xD;
             atrial fibrillation&#xD;
&#xD;
          4. Current treatment and compliance with standard anticoagulation regimen, including&#xD;
             uninterrupted OAC, with acceptable coagulation status, as determined by the Principal&#xD;
             Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subject must not meet any of the following exclusion criteria:&#xD;
&#xD;
          1. Life expectancy of 1 year or less&#xD;
&#xD;
          2. AF due to reversible causes (e.g., hyperthyroidism, valve disease)&#xD;
&#xD;
          3. History of DC Cardioversion which failed to convert to AF to Normal Sinus Rhythm&#xD;
&#xD;
          4. Currently in AF for more than 3 months continuously&#xD;
&#xD;
          5. Chronic, long-standing persistent, or permanent atrial fibrillation&#xD;
&#xD;
          6. Allergy or contraindication to anticoagulation therapy&#xD;
&#xD;
          7. Presence of intracardiac thrombus (confirmed with TEE or ICE)&#xD;
&#xD;
          8. Existing Left Atrial Appendage closure device&#xD;
&#xD;
          9. Severely Dilated Left Atrium &gt;5cm&#xD;
&#xD;
         10. LVEF&lt;35%&#xD;
&#xD;
         11. NYHA Class III or IV heart failure at the time of enrollment&#xD;
&#xD;
         12. History of embolic stroke, Transient Ischemic Attack (TIA) or other thromboembolic&#xD;
             event within the preceding 3 months.&#xD;
&#xD;
         13. Known hyper-coagulable state that increases risk of thrombus&#xD;
&#xD;
         14. History of myocardial infarction or coronary revascularization within the preceding 3&#xD;
             months.&#xD;
&#xD;
         15. History of sustained ventricular arrhythmia or cardiac arrest&#xD;
&#xD;
         16. Presence of chronically implanted lead in the CS&#xD;
&#xD;
         17. Presence of ventricular assist device, including intra-aortic balloon pump&#xD;
&#xD;
         18. Documented bradycardia (&lt;40 BPM) at the time of the study&#xD;
&#xD;
         19. Morbid obesity: BMI&gt;39 kg/m2&#xD;
&#xD;
         20. Presence of any prosthetic cardiac valve&#xD;
&#xD;
         21. History of significant tricuspid valvular disease requiring surgery&#xD;
&#xD;
         22. Moderate to severe mitral valve regurgitation (&gt;40% regurgitation fraction)&#xD;
&#xD;
         23. Cognitive or mental health status that would interfere with study participation and&#xD;
             proper informed consent&#xD;
&#xD;
         24. Cardiovascular anatomical defects that would complicate placement of the stimulation&#xD;
             leads required by the protocol, including congenital heart disease and cardiac vein&#xD;
             anomalies per the Investigator's discretion&#xD;
&#xD;
         25. Pregnancy confirmed by test within 7 days of procedure.&#xD;
&#xD;
         26. Inability to pass catheters to heart due to vascular limitations&#xD;
&#xD;
         27. Cardiovascular surgery or intervention within 1 month prior to enrollment or planned&#xD;
             for up to 1 month after enrollment (other than the planned treatment procedure)&#xD;
&#xD;
         28. Active endocarditis&#xD;
&#xD;
         29. Any other medical condition which may affect the outcome of this study or safety of&#xD;
             the subject as determined by the investigator&#xD;
&#xD;
         30. History of hemodynamic compromise due to valvular heart disease&#xD;
&#xD;
         31. Unstable CAD as determined by the investigator&#xD;
&#xD;
         32. Severe proximal three-vessel or left main coronary artery disease without&#xD;
             revascularization as determined by the investigator&#xD;
&#xD;
         33. History of Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia,&#xD;
             Congenital Heart Anomaly, Cardiac Amyloidosis or Cardiac Sarcoidosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D Hummel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University (OSU) Wexner Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dave Munneke, MS</last_name>
    <phone>6128049516</phone>
    <email>dmunneke@cardialen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tom Rasmussen, BA</last_name>
    <phone>7196596363</phone>
    <email>trasmussen@cardialen.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Janardhan AH, Gutbrod SR, Li W, Lang D, Schuessler RB, Efimov IR. Multistage electrotherapy delivered through chronically-implanted leads terminates atrial fibrillation with lower energy than a single biphasic shock. J Am Coll Cardiol. 2014 Jan 7-14;63(1):40-8. doi: 10.1016/j.jacc.2013.07.098. Epub 2013 Sep 26.</citation>
    <PMID>24076284</PMID>
  </reference>
  <reference>
    <citation>Li W, Janardhan AH, Fedorov VV, Sha Q, Schuessler RB, Efimov IR. Low-energy multistage atrial defibrillation therapy terminates atrial fibrillation with less energy than a single shock. Circ Arrhythm Electrophysiol. 2011 Dec;4(6):917-25. doi: 10.1161/CIRCEP.111.965830. Epub 2011 Oct 6.</citation>
    <PMID>21980076</PMID>
  </reference>
  <reference>
    <citation>Efimov I, Ripplinger CM. Virtual electrode hypothesis of defibrillation. Heart Rhythm. 2006 Sep;3(9):1100-2. Epub 2006 Mar 10.</citation>
    <PMID>16945810</PMID>
  </reference>
  <reference>
    <citation>Ambrosi CM, Ripplinger CM, Efimov IR, Fedorov VV. Termination of sustained atrial flutter and fibrillation using low-voltage multiple-shock therapy. Heart Rhythm. 2011 Jan;8(1):101-8. doi: 10.1016/j.hrthm.2010.10.018. Epub 2010 Oct 19.</citation>
    <PMID>20969974</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

